TM-25659
TM-25659 性质
| 沸点 | 768.0±70.0 °C(Predicted) |
|---|---|
| 密度 | 1.29±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO：≥ 135 mg/mL (269.68 mM)；水：< 0.1 mg/mL（不溶） |
| 形态 | 固体 |
| 酸度系数(pKa) | 4.15±0.10(Predicted) |
| 颜色 | 白色至米白色 |
TM-25659 用途与合成方法
TAZ
TM-25659 (2, 10, 20, 100 μM) enhances nuclear TAZ localization in a dose-dependent manner and attenuates PPARγ-mediated adipocyte differentiation by facilitating PPARγ suppression activity of TAZ.
TM-25659 (2, 10, 50 μM) enhances osteogenic gene expression and thereby increases osteoblast differentiation.
Cell Proliferation Assay
| Cell Line: | 3T3-L1 cells |
| Concentration: | 2, 10, 20, 100 μM |
| Incubation Time: | 6 days |
| Result: | Acted as a suppressor of PPARγ-dependent adipocyte differentiation [1] . |
TM-25659 (50 mg/kg, i.p., every other day for 2 weeks) suppresses bone loss in vivo and decreases weight gain in an obesity model.
TM-25659 has a favourable pharmacokinetic profile in rats. The plasma concentration of TM-25659 declines with an approximate t 1/2 of 7 or 10 h following i.v or p.o. administration respectively. The systemic clearance (CL) is 0.21 L×h -1 ×kg -1 and the volume of distribution at steady-state (1.91 L×h -1 ×kg -1 ) is larger than the volume of total body fluids.
| Animal Model: | C57BL6 mice (4- to 6-week-old ) |
| Dosage: | 50 mg/kg |
| Administration: | I.p., every other day for 2 weeks |
| Result: | Attenuated weight gain in these obese mice [1] . |
| Animal Model: | Adult male Sprague-Dawley rats |
| Dosage: | 10 mg/kg |
| Administration: | I.v. (2, 10 and 30 min), oral (15 and 30 min, and 1, 2, 4 and 8 h) |
| Result: | Oral administration for 4 weeks moderately but significantly attenuated weight gain and partly restored BMD in the OVX rats [1] . |
TM-25659 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-112920 | TM-25659 | 260553-97-7 | 5mg | 950 |
| 2024-11-08 | HY-112920 | TM-25659 | 260553-97-7 | 10mM * 1mLin DMSO | 1050 |
